A large body of evidence has accrued indicating that voltage-gated Ca 2ϩ channel subtypes, including L-, T-, N-, and P/Q-type, are present within renal vascular and tubular tissues, and the blockade of these Ca 2ϩ channels produces diverse actions on renal microcirculation. Because nifedipine acts exclusively on L-type Ca 2ϩ channels, the observation that nifedipine predominantly dilates afferent arterioles implicates intrarenal heterogeneity in the distribution of L-type Ca 2ϩ channels and suggests that it potentially causes glomerular hypertension. In contrast, recently developed Ca 2ϩ channel blockers (CCBs), including mibefradil and efonidipine, exert blocking action on L-type and T-type Ca 2ϩ channels and elicit vasodilation of afferent and efferent arterioles, which suggests the presence of T-type Ca 2ϩ channels in both arterioles and the distinct impact on intraglomerular pressure. Recently, aldosterone has been established as an aggravating factor in kidney disease, and T-type Ca 2ϩ channels mediate aldosterone release as well as its effect on renal efferent arteriolar tone. Furthermore, T-type CCBs are reported to exert inhibitory action on inflammatory process and renin secretion. Similarly, N-type Ca 2ϩ channels are present in nerve terminals, and the inhibition of neurotransmitter release by N-type CCBs (eg, cilnidipine) elicits dilation of afferent and efferent arterioles and reduces glomerular pressure. Collectively, the kidney is endowed with a variety of Ca 2ϩ channel subtypes, and the inhibition of these channels by their specific CCBs leads to variable impact on renal microcirculation. Furthermore, multifaceted activity of CCBs on T-and N-type Ca 2ϩ channels may offer additive benefits through nonhemodynamic mechanisms in the progression of chronic kidney disease. (Circ Res. 2007;100:342-353.) Key Words: afferent arteriole Ⅲ efferent arteriole Ⅲ Ca 2ϩ channel blockers Ⅲ renal microcirculation Ⅲ voltage-dependent Ca 2ϩ channels Ⅲ renal disease Ⅲ efonidipine Ⅲ mibefradil Original
T he kidney is supplied with a large amount of blood from the heart and is committed to multifaceted functions that are requisite for the preservation of body fluid and electrolyte homeostasis. Furthermore, the kidney is a major target organ for the complications in pathological conditions such as hypertension and diabetes, which would increase the risk for cardiovascular events. Numerous antihypertensive agents have been developed to blunt the progression of chronic kidney disease, including angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists. Ca 2ϩ channel blockers (CCBs) are also used widely as a first-line antihypertensive agent, and the inhibition of L-type Ca 2ϩ channels with CCBs, including nifedipine, diltiazem, and nitrendipine, elicits marked increases in glomerular filtration rate and renal blood flow. [1] [2] [3] [4] These observations indicate substantial distribution of L-type Ca 2ϩ channels within the renal vascular bed. Of note, it has been demonstrated that these CCBs elevate filtration fraction, 1-4 a marker for glomerular capillary pressure. Because glomerular filtration is controlled by preglomerular (afferent) and postglomerular (efferent) arterioles as well as the mesangial ultrafiltration, these CCBs may act predominantly on the preglomerular arterioles.
Recently, a growing body of evidence has accumulated showing important roles of T-type Ca 2ϩ channels in various organs, such as cardiac sinus node and adrenal gland, which serve to generate pacemaker potential and release aldosterone, respectively. 5 Furthermore, newly developed CCBs, including efonidipine, nilvadipine, and mibefradil, have been demonstrated to possess blocking activity on T-type as well as L-type Ca 2ϩ channels. 6 -9 Interestingly, these CCBs exert renal microvascular action distinct from conventional CCBs (eg, nifedipine); these agents cause a lower increase in filtration fraction 10 -12 and greater proteinuria-sparing action. 13, 14 Furthermore, the blockade of other Ca 2ϩ channel subtypes (eg, N-type) is reported to exert unique action that leads to reduction in glomerular hypertension. 15 Such renal action would allow us to speculate that T-type/N-type Ca 2ϩ channels participate in the regulation of the renal microvascular tone and that the distribution of these Ca 2ϩ channels differs from that of L-type Ca 2ϩ channels. The putative intrarenal distribution of these Ca 2ϩ channels implicates the kidney as a unique organ that would facilitate the characterization of Ca 2ϩ channel subtypes.
The purpose of this review is to provide an overview of the role of Ca 2ϩ channels in the kidney, with special references to Ca 2ϩ channels subtypes, including L-type, T-type, and N-type Ca 2ϩ channels. Furthermore, we review the current under-standing of the effect of CCBs in the renal microcirculation and the pathophysiological process of renal injury.
Ca 2؉ Channel Subtypes
Voltage-gated Ca 2ϩ channels are classified into L-, P/Q-, N-, R-, and T-type subtypes by their pharmacological and electrophysiological properties and comprise heteromeric multisubunits, including ␣ 1 , ␣ 2 , ␤, ␦, and ␥ (skeletal muscle). 16 Among these, the ␣ 1 subunit possesses main characteristics of the channel, such as ion-conducting pore, ion selectivity, and voltage sensitivity, and is encoded by CACNA1 gene family consisting of 10 genes (Figure 1 ). In the kidney, a number of Ca 2ϩ channels comprising various ␣ 1 16 ; precise or organized electrophysiological analyses, however, have not been conducted because the kidney contains divergent cell populations. Furthermore, the kidney is supplied with numerous nerve endings that contain N-type (␣ 1B ) Ca 2ϩ channels. Interestingly, P-(Ca V 2.1a) and Q-type Ca 2ϩ channel subunits (Ca V 2.1b) are splice variants of a single gene (ie, CACNA1A) and are expressed in the afferent arteriole. 17 Although splice variants have been demonstrated in neuronal and cardiac cells, 18 as well as in vascular smooth muscle cells from atherosclerotic tissues, 19 whether these variants affect the renal function remains undetermined.
Effect of CCBs on Renal Function and Microvessels
Afferent and efferent arterioles exist adjoining the glomerulus and adjust their vascular tone in response to various vasomotor stimuli. The responsiveness of these arterioles, however, should differ with respect to efficient adjustment of glomerular filtration. Indeed, atrial natriuretic peptide causes afferent arteriolar dilation and efferent arteriolar constriction. 20, 21 Furthermore, elevated renal perfusion pressure, 22 endothelin, 23 and high potassium 24 elicit predominant constriction of the afferent arteriole.
When administered in vivo, nifedipine causes a greater increase in glomerular filtration rate than that in renal plasma flow, resulting in elevated filtration fraction. 1,2 Furthermore, nicardipine 3 and verapamil 2,4 are reported to increase filtration fraction. These observations strongly suggest predominant action on the afferent arteriole. In the in vivo settings, however, systemic blood pressure is decreased, which may confound the effect of CCBs on renal arterioles. To eliminate the pressure-induced changes in vascular tone, Loutzenhiser and colleagues [25] [26] [27] [28] used the isolated perfused rat normal kidney model. This model allows constant renal perfusion pressure, whereby the myogenic tone of renal microvessels is unaltered. In a series of their experiments, they found that under angiotensin II-or norepinephrine-induced vasoconstrictor tone, CCBs including nifedipine, nisoldipine, diltiazem, and amlodipine caused greater increases in glomerular filtration rate than those in renal plasma flow, resulting in exaggerated increases in filtration fraction. [25] [26] [27] [28] Thus, these observations again support the formulation that the CCB acts predominantly on the renal preglomerular vessels.
Recent advance in renal physiology facilitates more direct observation of renal microcirculation. 21-24,30 -36 Ca 2ϩ sellas and Navar 34 developed an in vitro technique that allows direct visualization of the juxtamedullary nephron circulation. In their experiments, both verapamil and diltiazem potently inhibited the afferent arteriolar vasoconstriction, whereas efferent arterioles were relatively refractory to the vasodilator action of these agents. 37 Similarly, Ito and colleagues 32, 33 developed the isolated renal cortical microvessel model and found that nifedipine predominantly dilated the afferent arteriole. 38 Loutzenhiser, Epstein, and colleagues developed a model of the isolated perfused hydronephrotic kidney that facilitates direct observation of the renal microvasculature under defined in vitro conditions. [21] [22] [23] [24] Using this model, we demonstrated that both dihydropyridine class (eg, nifedipine, nicardipine, and amlodipine) and benzothiazepine class (eg, diltiazem) CCBs reversed the angiotensin II-induced constriction of the afferent arteriole, whereas the efferent arteriole was refractory to the vasodilator action of these antagonists. 39 ,40 Furthermore, we have observed that nifedipine causes predominant dilation of the afferent arteriole in the canine kidney, using the intravital pencil-lens charge-coupled device camera videomicroscopy ( Figure 2C ) (see below). 10 Alternatively, direct visualization of the renal microcirculation with the isolated perfused hydronephrotic kidney 24 and isolated microvessels 41 demonstrates that high K-induced membrane depolarization selectively constricts the afferent arteriole, whereas the efferent arteriole is relatively insensitive to the depolarization. Furthermore, a Ca 2ϩ channel agonist (eg, Bay K-8644), which directly activates voltagedependent Ca 2ϩ channels, causes preferential afferent arteriolar constriction. 42 The preferential afferent arteriolar action of the CCB suggests predominant distribution of L-type Ca 2ϩ channels in this vessel. Indeed, Hansen et al 43 have demonstrated that the mRNA encoding Ca 2ϩ v 1.2 (␣ 1C ) L-type Ca 2ϩ channel subunits is expressed in afferent arterioles from rabbit cortical preglomerular arterioles (Table) . In contrast, no subunit was found in cortical efferent arterioles, although these channel subunits were expressed at juxtamedullary efferent arterioles. Similarly, it has been demonstrated that Ca v 1.2 preferentially prevails at the rat afferent arteriole, whereas the efferent arteriole lacks in this subunit (K. Ono, personal communication, 2005). These observations thus endorse the functional evidence indicating preferential activity of L-type Ca 2ϩ channels at the afferent, but not efferent, arteriole.
Effect of T-Type CCBs on Renal Microvessels
In contrast to preferential action of the conventional types of CCBs on preglomerular arterioles, a growing body of evidence has been accumulated demonstrating that certain types of CCBs may affect postglomerular as well as preglomerular 
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vascular tone. 38 -40,44,45 Takabatake et al 46 found that the intravenous administration of manidipine caused a greater increase in renal plasma flow than that in glomerular filtration rate in spontaneously hypertensive rats (SHRs), resulting in decreased filtration fraction. Furthermore, nilvadipine is reported to increase renal plasma flow without any changes in glomerular filtration rate in humans. 12 Yokoyama et al 11 also reported that efonidipine potently increased renal plasma flow more markedly than glomerular filtration rate, causing a decrease in filtration fraction. Collectively, the observations obtained in vivo strongly suggest that these CCBs decrease efferent arteriolar resistance. Furthermore, the assessment of renal arteriolar resistance with the use of renal function curves indicates an efferent arteriolar dilation by benidipine in human nondiabetic nephropathy. 47 Very recently, a growing body of direct evidence for efferent arteriolar action of certain types of CCBs has accumulated. Tojo et al 48 have reported that manidipine elicits both afferent and efferent arteriolar dilation in the in vivo hydronephrotic kidney model, although the magnitude of the efferent arteriolar dilation is still less than that of the afferent arteriolar dilation. Using the microdissected renal arterioles, Arima et al 38 also reported that manidipine caused efferent as well as afferent arteriolar dilation. Furthermore, Kawabata et al 49 reported in a rat micropuncture study that efonidipine reduced both pre-and postglomerular capillary resistance. Finally, we have demonstrated that several CCBs, including nilvadipine, manidipine, benidipine, efonidipine, mibefradil, and aranidipine, cause substantial dilation of efferent arterioles in the isolated perfused rat hydronephrotic kidney ( Figure 3A ). 39, 40, 44, 45, 50 There exists some possibility that the results obtained from the hydronephrotic kidney model might be distorted because of the nature of its experimental setting. To circumvent this possibility, we further extended our premise, with the use of the intravital pencil-lens charge-coupled device camera videomicroscopy ( Figure 2B ). 10, 36, [51] [52] [53] [54] This experimental technique is unique because in vivo, in situ, and relatively intact renal microcirculation is accessible by simply introducing the pencil-lens probe into the renal cortex, without disrupting the renal microvascular responsiveness to tubuloglomerular feedback mechanism or angiotensin II. 36 Using this experimental technique, we confirmed heterogeneity in the action of CCBs on the renal microcirculation. Thus, nifedipine elicited predominant dilation of the afferent arteriole, whereas both efonidipine and mibefradil caused marked dilation of efferent, as well as afferent, arterioles ( Figure  2C ). 10 Finally, cilnidipine elicited substantial dilation of the efferent arteriole, although the vasodilator response was greater in the afferent arteriole. These findings parallel the observation that filtration fraction is elevated with nifedipine, is unaltered with cilnidipine, tends to decrease with efonidipine, and is reduced with mibefradil ( Figure 2A ). 55 Collectively, these results strongly support our formulation that the renal microvascular effects of CCBs vary depending on the types of the antagonists used.
Several pharmacological studies demonstrate that certain types of CCBs possess blocking activity not only on L-type but also on other types of Ca 2ϩ channels. Nickel chloride is a well-known CCB that inhibits the T-type Ca 2ϩ current, although the selectivity for T-type and L-type Ca 2ϩ current is not high. 56, 57 Mibefradil has been developed and is used as a selective T-type CCB, 8, 58 although it has been withdrawn from the market because of adverse effects related to drug interaction. 59 A series of the subsequent studies have revealed that numerous CCBs available for clinical use exert blocking The blocking activity on Ca 2ϩ channel subtypes are adapted from previous studies. 6 -9,60,61,66,100 B, Relative vasodilator action of CCBs on efferent versus afferent arterioles in the isolated perfused hydronephrotic kidney (in vitro) is compared with that in the in vivo hydronephrotic kidney (in vivo-1) or in the canine kidney (in vivo-2). CCBs with N-type blocking activity (amlodipine, cilnidipine, benidipine, and mibefradil) cause greater efferent vs afferent arteriolar dilation in vivo than that observed in vitro.
action on both L-type and T-type Ca 2ϩ current, including nilvadipine, manidipine, and efonidipine. 6, 7, 60 Recently, Furukawa and colleagues 60, 61 have surveyed the blocking activity of various CCBs on L-/T-/N-type Ca 2ϩ current in Xenopus oocytes. They demonstrate predominant action of nifedipine, nitrendipine, and nimodipine on L-type Ca 2ϩ channels, whereas these agents caused only modest inhibition of T-type Ca 2ϩ channels. In contrast, efonidipine, benidipine, and manidipine potently inhibited the T-type as well as L-type Ca 2ϩ channels.
The nature of the potent inhibitory action of T-type CCBs may bear on the efferent arteriolar action. In several microvasculature, including mesenteric 62 and cremaster arterioles, 63 T-type Ca 2ϩ channels are distributed substantially, and the blockade of these channels by mibefradil, a selective T-type CCB, inhibits the vasoconstriction of these arterioles. The effect of mibefradil, however, may be attributed to the blocking action on L-type Ca 2ϩ channels. 64 In the renal microvasculature, Hansen et al 43 have demonstrated that T-type Ca 2ϩ channels, as assessed by Ca V 3.1 (an ␣ 1 subunit of T-type Ca 2ϩ channels), prevail at juxtamedullary efferent arterioles, as well as afferent arterioles of superficial and juxtamedullary nephrons (Table) . Furthermore, the presence of a Ca v 3.1 subunit at superficial efferent, as well as afferent arterioles, has recently been found with the use of in situ hybridization (K. Ono, personal communication, 2005) . Consistent with these observations, Nakamura et al 65 found that mibefradil decreased both afferent and efferent arteriolar resistance in SHR kidneys, using the micropuncture technique. Ozawa et al 45 have directly visualized the efferent arteriolar dilation by T-type CCBs; both mibefradil and nickel chloride potently reverse the angiotensin II-induced constriction of the efferent arteriole in the isolated perfused rat hydronephrotic kidney model. Aranidipine, which has been reported to block both T-/L-type Ca 2ϩ channels, 66 potently dilates afferent as well as efferent arterioles in the same experimental model. 50 Similarly, Feng and colleagues 67, 68 showed that T-type CCBs, including pimozide and mibefradil, caused marked dilation of the efferent arteriole in the in vitro blood-perfused juxtamedullary nephron preparation. Collectively, these novel findings strongly suggest a critical role of T-type Ca 2ϩ channels in mediating the efferent arteriolar tone.
Some controversy remains regarding the role of T-type Ca 2ϩ channels in vascular tone. Recently, mice deficient in Ca V 3.2 T-type Ca 2ϩ channels manifest normal contractile responses but reduced relaxation in response to acetylcholine. 69 Moosmang et al 64 have also demonstrated that mibefradil has no effect on blood pressure or peripheral resistance in conditional knockout mice of Ca V 1.2 L-type Ca 2ϩ channels. Indeed, we have found that R(Ϫ)-enantiomer of efonidipine, which possesses more selective blocking activity on T-type Ca 2ϩ channels than efonidipine, [71] [72] [73] fails to reduce blood pressure in hypertensive rats. 74 Nevertheless, angiotensin II upregulates the Ca V 3.1 T-type Ca 2ϩ channels in vascular smooth muscle cells. 74 Furthermore, we and other laboratories have found that the Ca V 3.1 subunit is substantially expressed in the kidney, 43, 74, 75 where angiotensin II is abundantly present. Finally, Ozawa et al 45 showed that mibefradil completely inhibited the nifedipine-resistant renal efferent arteriolar tone preconstricted by angiotensin II. It requires further investigations, however, to determine whether T-type Ca 2ϩ channels, particularly Ca V 3.1 (␣ 1G ), serve to control the renal microvascular tone.
Besides afferent and efferent arterioles, T-type Ca 2ϩ channels are reported to be present in other renal vascular segments. Hansen et al 43 have demonstrated that Ca V 3.1 and Ca V 3.2 are present in vasa recta (Table) . In combination with the previous finding that efonidipine causes efferent arteriolar dilation, 10, 38, 39 the elevated luminal pressure at the vasa recta would diminish tubular sodium reabsorption and, therefore, may contribute to the greater natriuresis by efonidipine than by nifedipine. 55
Mechanism for T-Type CCB-Induced Efferent Arteriolar Vasodilation
A recent pharmacological study has indicated that efonidipine possesses the blocking activity on T-type, as well as L-type, voltage-dependent Ca 2ϩ channels. 6, 60 Although T-type Ca 2ϩ channels are closely associated with pacemaking potentials, 57 the role of these Ca 2ϩ channel subtypes in the vasculature remains poorly understood. Furthermore, the mechanism whereby T-type Ca 2ϩ channel activity modifies the intracellular vasoconstrictor signaling pathway, and thus dilates efferent arterioles, remains unknown. Angiotensin II-induced vasoconstriction of renal arterioles involves 2 main intracellular signaling pathways, protein kinase C (PKC) and inositol-1,4,5-trisphosphate (IP 3 )induced intracellular Ca 2ϩ release. 76, 77 In the efferent arteriole, we previously demonstrated that during angiotensin II stimulation, both PKC-and IP 3 -associated vasoconstrictor mechanisms were activated in an additive manner. 65, 66 In this regard, mibefradil is reported to inhibit the PKC-mediated signaling pathway and prevent the vascular smooth muscle contraction in the vascular smooth muscle cell. 78 Furthermore, Sipido et al 79 reported that T-type channel activation facilitated Ca 2ϩ2ϩ release from sarcoplasmic reticulum in cardiac myocytes. We therefore examined the interaction between these intracellular mechanisms and mibefradilinduced vasodilation. Thus, the PKC-mediated pathway is relatively refractory to the vasodilator action of mibefradil. In the presence of thapsigargin, whereby angiotensin II should stimulate the PKC-mediated vasoconstrictor pathway dominantly, 76, 77 mibefradil had only a modest effect on the efferent arteriolar constriction. In contrast, in the presence of staurosporine, the angiotensin II-induced vasoconstriction of efferent arterioles is highly sensitive to the vasodilator action of mibefradil. Because staurosporine prevents the PKCmediated constrictor mechanism, the major remaining vasoconstrictor mechanism of angiotensin II should be an IP 3mediated Ca 2ϩ release pathway. 76, 77 In concert, these observations are consistent with the view that that the IP 3 -mediated pathway constitutes an important target for the action of mibefradil during the angiotensin II-induced arteriolar constriction.
Although the link between T-type Ca 2ϩ channels and sarcoplasmic Ca 2ϩ release remains undetermined, recent investigations suggest an intimate interaction between the plasma membrane and the endoplasmic reticulum, which is proposed as a conformational coupling model. 80 Thus, T-type Ca 2ϩ channels within the plasma membrane may communicate with the sarcoplasmic Ca 2ϩ regulation. Indeed, T-type channel activation is reported to facilitate Ca 2ϩ release from sarcoplasmic reticulum in cardiac myocytes. 79, 81 Further studies are required to determine how T-type Ca 2ϩ channels interact with this constrictor mechanism.
Additional mechanisms for the efferent arteriolar dilation by recently developed CCBs merit comment. It has been reported that T-type Ca 2ϩ channel activation stimulates renin release. Wagner et al 82 have demonstrated that mibefradil suppresses renin release. This observation raises the possibility that T-type Ca 2ϩ channel blockade inhibits angiotensin II production and, therefore, would be anticipated to contribute in part to the efferent arteriolar vasodilation. Furthermore, Arima and colleagues 83, 84 have recently demonstrated that aldosterone causes efferent arteriolar constriction that involves T-type Ca 2ϩ channel-mediated vasomotor tone. Finally, we have recently found that mibefradil and efonidipine prevent the angiotensin II-induced stimulation of the Rhokinase pathway in vascular smooth muscle cells. 85 Because Rho-kinase enhances the vascular tone of the efferent arteriole, 86 -90 it is anticipated that Rho-kinase mediates the efferent arteriolar tone induced by T-type Ca 2ϩ channels.
Role of N-Type and P/Q-Type Ca 2؉ Channels in Renal Microvascular Tone
Besides L-type and T-type CCBs, several CCBs possessing both L-and N-type Ca 2ϩ channel-blocking activity have been developed, 91, 92 and cilnidipine is clinically available in Japan. 93, 94 This class of the CCB is unique because of its pharmacological characteristics, ie, the inhibitory action on norepinephrine secretion 95, 96 and neurally stimulated renal vasoconstriction. 97 As shown in Figure 3A , both cilnidipine and pranidipine elicit predominant action on the afferent arteriole in the in vitro isolated perfused hydronephrotic kidney. 98 In contrast, we also found that cilnidipine caused substantial vasodilation of efferent, as well as afferent, arterioles in the canine kidney in vivo ( Figure 2C ). Similar findings have been reported in a study using the in vivo hydronephrotic kidney model 99 ( Figure 3B ) and in a renal micropuncture study showing decreases in both afferent and efferent arteriolar resistance in nitro-L-arginine methyl estertreated SHRs. 15 Because the sympathetic nerve is distributed along afferent and efferent arterioles, the inhibition of N-type Ca 2ϩ channels would dilate both arterioles. Indeed, amlodipine, which possesses the inhibitory action on L-type and N-type Ca 2ϩ channels, 61,100 is reported to cause substantial dilation of efferent, as well as afferent, arterioles in the in vivo hydronephrotic kidney, 101 whereas it predominantly dilates the afferent arteriole in the in vitro isolated perfused hydronephrotic kidney ( Figure 3B ). 39 Furthermore, the ability of benidipine and mibefradil to dilate the efferent arteriole is exaggerated in the in vivo hydronephrotic kidney (K. Kimura, personal communication, 1994) and in the canine kidney in vivo, 10 respectively, when compared with the action observed in the in vitro isolated hydronephrotic kidney. 45, 102 In contrast, no such enhancement is observed with nifedipine or manidipine, neither of which possesses N-type Ca 2ϩ channelblocking activity. The apparently discrepant observations in the in vivo and in vitro experimental settings suggest the requirement of the integrity of sympathetic nerves for the full action of N-type CCBs. Several recent studies extend our knowledge regarding the distribution of P/Q-type Ca 2ϩ channels, which have been reported to prevail abundantly in neuronal cells. Hansen and colleagues 17, 103 demonstrated the presence of Ca V 2.1 (␣ 1A ) in rat preglomerular arterioles, using RT-PCR and immunostaining (Table) . They further showed that the functional role of P/Q-type Ca 2ϩ channels in mediating the KCl-induced constriction of the afferent arteriole. 17 In concert, available evidence indicates that several Ca 2ϩ channel subtypes are present in the kidney and serve to modulate the renal microvascular tone.
Ca 2؉ Channel Subtypes in Renal Tubules
It has been demonstrated that Ca V 1.2 (␣ 1C ) is expressed in cells of the distal tubules as well as outer and inner medullary collecting ducts (Table) . 104 Although this channel subtype is localized more predominantly on the basolateral membrane than apical membrane, physiological roles of this channel remain undetermined.
Andreasen et al 75 examined the nephron localization of Ca V 3.1 (␣ 1G ) in the inner medullary collecting ducts, distal collecting ducts and connecting tubules, particularly on the apical site (Table) . On the basis of the fact that epithelial sodium channels are localized to the same cells, depolarization induced by sodium absorption through epithelial sodium channels could activate apical T-type Ca 2ϩ channels.
A recent investigation by Brunette et al 105 has indicated that several CCBs, including diltiazem, mibefradil, and -conotoxin MVIIC (a P/Q-type CCB), inhibit the Ca 2ϩ2ϩ transport through the membrane from the distal tubule. They suggest that these channels belong to the L-type, T-type, and P/Q-type Ca 2ϩ channels. The functional significance of these channels requires further investigation. Ca 2ϩ overload induced by ischemia 106 and chronic renal injury 107 teleologically may be prevented by the blockade of these Ca 2ϩ channels.
Hemodynamic Effects of L-/T-/N-Type CCBs in Renal Injury
Based on the renal microcirculatory action, it is inferred that whereas the depressor action of traditional CCBs favors an attenuation of glomerular hypertension and the subsequent renal protection, 98,108 -110 the predominant activity on preglomerular vessels might cause glomerular hypertension that could finally be associated with the progression of kidney diseases. [111] [112] [113] [114] [115] Thus, the changes in these 2 factors may vary depending on the experimental settings, magnitude of depressor activity, and types of the CCBs used. Thus, verapamil is reported to reduce proteinuria and protect against renal injury in remnant kidney models. 116, 117 Furthermore, Dworkin and colleagues 118 -120 demonstrated that nifedipine reduced both urinary protein excretion and glomerular injury in subtotally nephrectomized rats, uninephrectomized SHRs, and deoxycorticosterone acetate (DOCA)-salt hypertensive rats, despite the persistent glomerular hypertension. Contrasting results have also been reported indicating deleterious effects of dihydropyridine class CCBs in kidney diseases. [111] [112] [113] [114] 118, 121, 122 Wenzel et al 121 demonstrated that nitrendipine increased proteinuria and glomerulosclerosis in a 2-kidney, 1-clip model of hypertension. Furthermore, Dworkin et al 118 found that amlodipine did not exhibit renoprotective action in DOCA-salt hypertensive rats. In the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), glomerular filtration rate was well preserved in patients on amlodipine therapy during the trial period, when compared with patients on lisinopril or chlorthalidone treatment. 123 In a large-scale clinical trial evaluating the renal protective effect of antihypertensive agents in African-Americans with hypertensive kidney disease (AASK), however, amlodipine is less effective in retarding the decline of renal function than ramipril. 124 Thus, the ability of the CCBs with predominant activity on afferent arterioles may vary depending on the level of blood pressure achieved. In contrast, novel CCBs acting on both afferent and efferent arterioles theoretically correct glomerular hypertension and could exert salutary actions on the progression of renal injury. Shudo and colleagues [125] [126] [127] reported that efonidipine acutely decreased proteinuria in spontaneously hypertensive rats, whereas systemic blood pressure was only partially reduced. Furthermore, Fujimaki et al 128 found that manidipine exerted salutary action on renal structure in uninephrectomized spontaneously hypertensive rats. Mibefradil has also been reported to mitigate renal injury in SHRs 65 and DOCA hypertensive rats. 129, 130 A similar beneficial effect was observed with aranidipine, 50 which possessed the blocking activity on T-type Ca 2ϩ channels. 66 In this regard, we previously demonstrated that 8-week treatment with efonidipine markedly prevented the increase in proteinuria, whereas nifedipine did not reduce it despite the same reduction in systemic blood pressure. 13 Of note, efonidipine reduced proteinuria to the same level as enalapril, which causes both afferent and efferent arteriolar dilation. The salutary action of the T-type CCB is also evident in a clinical setting. Thus, in patients with nondiabetic kidney disease, 12-month treatment with efonidipine reduced proteinuria to the same level as that with angiotensin-converting enzyme inhibitors. 131 Of importance, in the patients in whom mean systemic blood pressure did not achieve a level below 100 mm Hg, proteinuria was significantly decreased. Although obviously the beneficial effects of T-type CCBs are not totally ascribed to glomerular hemodynamic action, the proteinuria-reducing effect of T-type CCBs would suggest an important role of a glomerular hemodynamic factor (ie, efferent arteriolar dilation) in blunting the progression of renal disease.
Analogous to the action of T-type CCBs, N-type CCBs would modulate glomerular capillary pressure and subsequently provide beneficial action in renal disease. Cilnidipine has been reported to suppress the elevation in blood pressure and blunt the progression of renal injury in Dahl saltsensitive rats 132 and ameliorate glomerular injury and proteinuria in Dahl rats with high-sucrose diet. 133 Furthermore, this CCB exerts antiproteinuric action in patients with essential hypertension. 134 A caveat is in order, however, because preferential afferent arteriolar dilation following renal injury 135 may influence the action of CCBs. Thus, the ability of afferent arterioleselective CCBs to ameliorate glomerular hypertension may depend largely on whether systemic hypertension is corrected in this circumstance. In contrast, the CCBs acting on efferent arterioles would predispose glomerular capillary pressure to reduce in addition to hypotensive action. Consequently, the contrasting effects of these antihypertensive agents on proteinuria may be unique in chronic kidney disease.
Nonhemodynamic Effects of L-/T-/N-Type CCBs in Renal Injury
Besides glomerular capillary pressure, multiple mechanisms appear to contribute to the ability of CCBs to protect against renal injury. For example, CCBs (nifedipine and cilnidipine) are reported to prevent mesangial cell proliferation by inhibiting activator protein-1. 136 CCBs are also shown to suppress the cell cycle transition from the G 1 to S phase (benidipine) 137 and modulate gene transcriptions that are involved in proinflammatory changes, such as interleukin-1␤ and granulocyte/ monocyte colony stimulating factors (manidipine). 138 Furthermore, CCBs could act as free radical scavengers (nifedipine, amlodipine, nilvadipine). 139 -141 Finally, CCBs (nifedipine and benidipine) inhibit the apoptotic or necrotic processes induced by tumor necrosis factor-␣ or cycloheximide. 142 Although the observations described above lend support to the premise that the CCB exerts salutary actions in renal injury process, it remains undetermined whether these effects are mediated by the blockade of specific Ca 2ϩ channel subtypes. It has been shown that T-type Ca 2ϩ channels participate importantly in cell differentiation and proliferation 143 and contribute to the platelet-derived growth factorinduced vascular smooth muscle cell migration. 144 These pathophysiological processes could reflect inflammatory tissue injury and may emerge in kidney disease. Indeed, efonidipine has been shown to suppress the A23187ϩphorbol myristate acetate-induced activation of nuclear factor-B in cultured human mesangial cells. 145 In contrast, L-type CCBs (verapamil and nifedipine) have no effect on this activation. Furthermore, Baylis et al 130 demonstrated that 4 to 5 weeks of administration of mibefradil to DOCA-salt rats ameliorated proteinuria and glomerular damage, whereas amlodipine failed to improve renal injury. Of note, both amlodipine and mibefradil exerted similar antihypertensive actions and decreased glomerular capillary pressure to the same level. Based on the properties of these CCBs, it appears that the T-type CCB confers greater benefit, distinct from that provided by the L-type CCB.
Recent investigations have demonstrated that Rho-kinase participates in the progression of various types of renal disease, 89, 147 including subtotally nephrectomized rats, 148 Dahl salt-sensitive rats, 149 DOCA-salt rats, 150 and angiotensin II-infused renal injury. 151 We have found that mibefradil and efonidipine suppress the angiotensin II-stimulated Rhokinase activity more pronouncedly than nifedipine in vascular smooth muscle cells. 85 Furthermore, R(Ϫ)-enantiomer of efonidipine (a more selective T-type CCB) downregulates GTP-RhoA (an upstream molecule for Rho-kinase). When administered to subtotally nephrectomized rats, R(Ϫ)enantiomer of efonidipine fails to reduce blood pressure but markedly suppresses proteinuria and tubulointerstitial changes. 74 Although the possibility remains that this CCB affects glomerular capillary pressure and subsequently ameliorates renal pathological damages, the striking improvement in the renal tubulointerstitial fibrosis suggests that direct salutary actions of the T-type CCB contribute to the amelioration of tubulointerstitial injury rather than the glomerular hemodynamic action. 130 Finally, it has recently been demonstrated that the angiotensin II signaling pathway enhances T-type Ca 2ϩ current 152 and upregulates Ca V 3.1 in cardiomyocytes. 153 We also have found that angiotensin II enhances the expression of Ca V 3.1 in vascular smooth muscle cells and mesangial cells. 74 Furthermore, the increased expression of Ca V 3.1 is observed in the renal tissue from subtotally nephrectomized rats, in which intrarenal angiotensin II contributes to the progression of renal injury. 74 This observation therefore allows speculation that the T-type Ca 2ϩ channel blockade offers more pronounced renal protective effect in chronic kidney disease.
A growing body of evidence has accumulated indicating that aldosterone promotes renal injury. 154, 155 Conversely, the blockade of aldosterone action exerts salutary effect on the progression of renal injury in both humans 156, 157 and experimental animals. 155, 158 Rossier et al 159 found that the aldosterone release provoked by angiotensin II and KCl was inhibited by mibefradil but not by nicardipine, suggesting an important contribution of T-type Ca 2ϩ channels to aldosterone release. Lotshaw 160 has reported similar results, showing an important role of T-type Ca 2ϩ channels in mediating the aldosterone secretion from adrenal glomerulosa cells. Furthermore it has recently been demonstrated that efonidipine is more potent than nifedipine in inhibiting the angiotensin IIand KCl-induced aldosterone secretion from H295R cells. 161 Of note, aldosterone is reported to induce renal injury partly through the activation of Rho-kinase, 162 and the Rho-kinase pathway is suppressed by a selective T-type CCB, R(Ϫ)enantiomer of efonidipine. 85 Collectively, the T-type CCB serves to mitigate the renal injury in which aldosterone play a role as a deteriorating factor.
The pharmacological action of N-type CCBs in kidney disease merits comment. Because N-type CCBs inhibit sympathetic nerve activity, [95] [96] [97] this type of the CCB could exert beneficial action in chronic kidney disease, in which sympathetic nervous system activity is increased. 163, 164 Indeed, Konda et al 132 demonstrated that 8-week treatment with cilnidipine decreased plasma concentrations of norepinephrine and renin activity and caused reductions in blood T-type (TCC) and N-type Ca 2ϩ (NCC) channels prevail in both afferent and efferent arterioles or the nerve terminals along these arterioles, and their inhibition elicits vasodilation of both arterioles, leading to the reduction in glomerular pressure. TCCs are also present in renal tubules, and in combination with efferent arteriolar dilation, the TCC inhibition would facilitate natriuresis. Furthermore, TCC blockers prevent the formation of nuclear factor-B (NF-B) and suppress Rho-kinase, which then mitigates the inflammatory process in the glomerulus and the interstitium. Finally, TCCs participate in the release of renin and aldosterone, and conversely the effect of aldosterone on renal arterioles is mediated by TCCs. Thus, the inhibition of these Ca 2ϩ channels exerts beneficial action through hemodynamic and nonhemodynamic mechanisms. pressure and improvement in glomerular sclerosis in Dahl salt-sensitive rats. Furthermore, they compared the effects of cilnidipine with those of amlodipine on the progression of renal injury in Dahl salt-sensitive rats fed a high-sucrose diet and found that cilnidipine provided superior protection against renal damage compared with amlodipine. 133 Although amlodipine also possesses N-type Ca 2ϩ channel-blocking activity, 61,100 the elevated levels of urinary norepinephrine excretion and renal renin mRNA expression suggest that the N-type blocking activity of amlodipine is not as potent as that of cilnidipine. Another N-type CCB, pranidipine, 92 is also shown to reduce blood pressure and exert antiproteinuric and renoprotective actions in subtotally nephrectomized rats 98 and Dahl salt-sensitive rats. 165 Although pranidipine does not dilate the efferent arteriole in the in vitro isolated perfused hydronephrotic kidney, 98 the property of N-type Ca 2ϩ channel-blocking action within this CCB could lead to the direct alterations in glomerular hemodynamics.
Concluding Remarks
Substantial advances have been made regarding our knowledge of the renal distribution of Ca 2ϩ channel subtypes. Furthermore, characterization of the CCB facilitates the renal action of this class of the agent (Figure 4 ). It is established that L-type CCBs cause predominant dilation of the afferent arteriole. In contrast, a large amount of evidence has accrued indicating that T-type CCBs exert renal protective action by ameliorating glomerular microcirculation with the property of vasodilator action on both afferent and efferent arterioles. Additionally, the blockade of T-/N-type Ca 2ϩ channels act to suppress inflammatory processes, renin-angiotensin-aldosterone system, Rho-kinase pathway, and sympathetic nervous system. Such multifaceted activity of T-type and N-type CCBs would be anticipated to protect against renal injury and may constitute a potential target for the treatment of hypertension with chronic kidney disease.
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